Table 2 Correlations between TILS (continuous) and clinical pathological characteristics
All cohort (n = 110) | Cohort TILs on metastatic site (n = 57) | ||||
---|---|---|---|---|---|
Parameters | TILs median (IQR) | p-valuea | TILs median (IQR) | p-valuea | |
Menopausal status | |||||
Premenopausal | 10 (5–15) | 0.323 | 10 (5–15) | 0.090 | |
Postmenopausal | 10 (5–20) | 10 (5–20) | |||
Stage at diagnosis | |||||
M0 | 10 (5–15) | 0.472 | 10 (5–15) | 0.368 | |
M1 | 10 (5–20) | 12.5 (5–20) | |||
Neoadjuvant chemotherapy | |||||
No | 10 (5–20) | 0.306 | 10 (5–17.5) | 0.534 | |
Yes | 10 (5–15) | 10 (5–15) | |||
ER status | |||||
Negative | 10 (6.3–15) | 0.083 | 10 (5–15) | 0.788 | |
Positive | 10 (5–15) | 10 (5–20) | |||
PR status | |||||
Negative | 10 (5–15) | 0.279 | 10 (5–15) | 0.836 | |
Positive | 10 (4–15) | 10 (2.5–20) | |||
HR statusb | |||||
Negative | 10 (6–15) | 0.080 | 10 (5–15) | 0.788 | |
Positive | 10 (5–15) | 10 (5–20) | |||
HER2 status | |||||
2+ | 10 (5–15) | 0.889 | 10 (5–17.5) | 0.151 | |
3+ | 10 (5–15) | 10 (5–15) | |||
Visceral disease | |||||
Yes | 10 (5–15) | 0.048 | 10 (5–11.3) | 0.428 | |
No | 15 (5–20) | 15 (5–15) | |||
Brain disease | |||||
Yes | 15 (10–15) | 0.383 | 5 (3.5–10) | 0.444 | |
No | 10 (5–15) | 10 (5–15) | |||
Site of TILs evaluation | |||||
Metastatic site | 10 (5–15) | 0.590 | Liver | 5 (5–10) | 0.0313 |
Lung | 15 (10–30) | ||||
Lymph node | 12.5 (2.8–18.8) | ||||
Soft Tissue | 10 (5.0–16.3) | ||||
Bone | 7.5 (3.8–11.3) | ||||
Primary BC | 10 (5–15) | // | |||
Best response | |||||
Complete response | 12.5 (8.8–15) | 0.554 | 10 (7.5–15) | 0.148 | |
Partial response | 10 (5–15) | 7.5 (5–15) | |||
Stable disease | 10 (5–20) | 10 (5–20) | |||
Progression disease | 10 (10–15) | 2 (2–2) | |||
Alive status | |||||
Alive | 10 (5–15) | 0.088 | 10 (5–15) | 0.010 | |
Dead | 5 (5–15) | 5 (2.8–10) |